The ASX 200 is having another off day…
The post ASX 200 midday update: ResMed’s US$1bn acquisition, tech shares continue to sink appeared first on The Motley Fool Australia. –
At lunch on Wednesday, theÂ S&P/ASX 200 Index (ASX: XJO) has recovered from its intraday low but remains in the red. The benchmark index is currently down 0.25% to 6,668.4 points.
Hereâs what is happening on the ASX 200 today:
Rio Tinto shares lift on Gudai-Darri update
After a soft start to the day, the Rio Tinto Limited (ASX: RIO) share price is now pushing higher. This follows news that the mining giant has delivered its first ore from the Gudai-Darri iron ore mine in the Pilbara, Western Australia. The Gudai-Darri iron ore mine will help underpin future production of the companyâs flagship Pilbara Blend product.
Tech shares continue to tumble
The tech sector is under pressure again on Wednesday, with the likes of Block Inc (ASX: SQ2) and Xero Limited (ASX: XRO) posting disappointing declines. This has led to the S&P ASX All Technology index losing a further 1.7% of its value today. This means the technology index is now down 39% since the start of the year.
ResMedâs US$1bn acquisition
The ResMed Inc (ASX: RMD) share price is trading lower despite the sleep treatment company announcing a major acquisition. ResMed has signed an agreement to acquire Medifox Dan for US$1 billion. It is a German leader in out-of-hospital software solutions for providers in major settings across the care continuum. Management believes the deal will strengthen the companyâs position as a global leader in healthcare software solutions.
Best and worst ASX 200 performers
The best performer on the ASX 200 has been the Lynas Rare Earths Ltd (ASX: LYC) share price with a 4.5% gain. This morning Macquarie reiterated its outperform rating and $12.80 price target on this rare earths producer’s shares. This was in response to yesterday’s announcement. Going the other way, the worst performer has been the Novonix Ltd (ASX: NVX) share price with an 8% decline on no news. Its shares are now down 75% in 2022.
The post ASX 200 midday update: ResMed’s US$1bn acquisition, tech shares continue to sink appeared first on The Motley Fool Australia.
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of January 12th 2022
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
This fund manager is optimistic on these 2 leading ASX 200 energy shares
ResMed share price drops despite US$1bn Medifox Dan acquisition
Rio Tinto share price lower despite Gudai-Darri update
Why I think these 2 ASX 200 dividend shares offer great buying right now
Warning: 1970s inflation is returning. Expert reveals what to do
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block, Inc., ResMed Inc., and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended Block, Inc., ResMed Inc., and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.